Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutant NSCLC(ZENITH20-5). Meeting Abstract

International Collaboration

cited authors

  • Le, Xiuning; Shum, Elaine; Suga, Jennifer M.; Brahmer, Julie R.; Dooms, Christophe; Mamdani, Hirva; Nechushtan, Hovav; Riess, Jonathan W.; Spira, Alexander; Barrett, John A.; Dreiling, Lyndah K.; Socinski, Mark

authors

Publication Date

  • July 1, 2021

webpage

published in

category

volume

  • 81

issue

  • 13